INTRODUCTION
Globally, approximately 150 million people are infected with hepatitis C virus (HCV), and it is estimated that up to 700 000 people die each year from HCV-related liver disease -predominantly from either liver cirrhosis or hepatocellular carcinoma ]. Worldwide, viral hepatitis (from hepatitis B virus and HCV combined) is causing more deaths than HIV/AIDS.
There is a high burden of hepatitis C in lowincome and middle-income countries (L&MICs), including resource-constrained settings such as India and Central Africa [3] . In these countries, the standard treatment is pegylated interferon and ribavirin (PEG-RBV). This is a complex treatment that involves significant toxicity, a relatively high cost and relatively poor efficacy and requires complex diagnostics and monitoring [4 && ]. The complexity and cost of currently required diagnostics serves as a major barrier preventing scale up and decentralization in low-resource contexts. However, the emergence of more effective and safe direct-acting antivirals (DAAs) [5 && ,6-8] offers the opportunity to significantly simplify the diagnostic and monitoring algorithm, thus decreasing costs and complexity and facilitating potential scale up in L&MICs.
With improvements to diagnostic technologies, there is the opportunity to significantly simplify diagnosis and monitoring before and after DAA treatment. This simplification of the laboratory package could greatly improve the feasibility of treating HCVinfected individuals living in resource-limited settings.
The diagnostic package required for case detection and monitoring of treatment for HCV using PEG-based therapies is complex, expensive and largely prohibitive for L&MICs. Minimum laboratory tests performed before, during and after treatment for hepatitis C are summarized in Fig. 2 .
Pretreatment tests typically include HCV serology, viral load and genotype [8] . In addition, because PEG-RBV is associated with relatively frequent toxicity and, especially for genotypes 1 and 4, only results in sustained virologic response in 50-70% of patients, guidelines may suggest delaying initiation of PEG-RBV until significant fibrosis is demonstrated and the clinical benefit of treatment is clear. Thus, a staging test to assess degree of fibrosis is often performed. Noninvasive markers of fibrosis, in particular transient elastography (fibroscan), are now very useful to stage liver fibrosis and avoid expensive and invasive liver biopsy [9] . In high-income countries, biomarkers with prognostic value for the success of interferon-based therapy, such as interleukin-28B (IL-28B), have also been recommended in difficult to treat genotypes 1 and 4 [10] . Due to the toxic side-effects of interferon-a, and teratogenicity of ribavirin, monthly laboratorybased monitoring is recommended. Complete blood count, alanine transaminase (ALT), creatinine, thyroid stimulating hormone and, in women of reproductive age, pregnancy testing must be monitored regularly during therapy. There are typically 5-6 HCV viral load measurements while on therapy [11] . Alpha-fetoprotein and ultrasonography are also used to exclude hepatocellular carcinoma.
Taken together, the complexity and cost of this diagnostic package represents yet another barrier to HCV treatment and care in L&MICs. First, many of these laboratory tests, such as HCV viral load, genotype and IL-28B, are expensive, and require
KEY POINTS
Currently, there is a complex set of diagnostic tests performed before, during and after treatment to cure hepatitis C. This includes genotyping, disease staging by fibroscan, HCV RNA PCR analysis and several other laboratory tests.
New combinations of DAAs can cure hepatitis C infection in a high percentage of patients.
It may be possible to simplify the set of diagnostic tests performed. Genotyping and disease staging may no longer be needed if treatments have pan-genotypic activity and work for people with and without liver cirrhosis.
Hepatitis C core antigen testing is cheaper and less complex to perform than HCV RNA PCR analysis. The use of antigen testing to confirm chronic infection before treatment, and then confirm cure after treatment, could simplify diagnostic requirements. [12] . In many African settings and HIV-HCV coinfected patients, false-positive and false-negative results are common [13] [14] [15] . The current test preferred by Médecins Sans Frontieres for its performance characteristics and GMP certification is the OraQuick HCV Rapid antibody test (Orasure, Pennsylvania, USA) -but at over 10 euros per test for general purchase, this test is also about 10 times the price of other serology tests and represents a significant barrier to its increased use. Furthermore, the staging diagnostics required are not ideally suited to decentralized care and lowincome settings. Transient elastography is expensive and the technology required is rarely available outside large cities. Thus, people living in peripheral areas are excluded from screening and care of viral hepatitis. Thus, its optimal use is in a referral center, which may be difficult to get to for patients without resources and little access to efficient transportation. Simple nonpatented biomarkers (e.g. AST to platelet ratio index or Fibrosis-4) that require the measurements of only platelets and transaminases have poor sensitivity and specificity particularly in HIVinfected individuals, and none of them have been validated in African patients who frequently experience thrombocytopenia [16, 17] . Finally, the overall cost of this diagnostic package may be prohibitively high for many L&MICs.
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POTENTIAL FOR SIMPLIFIED DIAGNOSTICS DURING DIRECT-ACTING ANTIVIRAL TREATMENT
All-oral, interferon-free DAA therapies may significantly reduce the need for complex diagnostic testing. New diagnostic tools are being developed that are better suited for use in resource-poor settings. Potentially pan-genotypic combinations may eliminate the need for genotyping. As phase II and III trials are showing therapy efficacy up to 87-100% for treatment-naive patients [4 && ], staging may become unnecessary as the risk-benefit ratio of therapy now bends much more toward benefit for the vast majority of patients, regardless of liver fibrosis stage [18] . This is particularly true for HCV-HIV coinfected patients who tend to progress more frequently and more rapidly than those who are HCV monoinfected [19] . If staging is still necessary for monoinfected patients, where resources to provide treatment are constrained, new simple and affordable indirect blood tests are needed.
DAA treatment with fewer associated adverse events will also require less laboratory monitoring. It is possible that only regular monitoring of ALT, aspartate aminotransferase, platelets, hemoglobin and creatinine will be required during therapy, and pregnancy testing, if ribavirin is still used. As response-driven treatment algorithms will be a thing of the past with new DAA regimens, the number of virological tests can be reduced to an initial confirmatory virological test and a post treatment virological test to prove cure [i.e. 12 weeks posttreatment sustained virologic response (SVR12)]. The marked reduction in the number of tests required will also dramatically drop the full cost of the diagnostic package (Fig. 3 ).
HEPATITIS C ANTIGEN TESTS AVAILABLE
Although currently, quantitative HCV RNA, or viral load, testing is used more commonly (to measure response to interferon-based treatment, which requires a log drop calculation from baseline), given that new DAA regimens will only require the confirmation of chronic HCV infection and the confirmation of cure, qualitative virological tests may be used. These have the added benefits of potentially being cheaper and simpler to develop and perform.
Advances in laboratory technology may also provide diagnostics better adapted to resource-limited environments. Antigen-based tests, such as those measuring HCV core antigen (cAg), could be used to replace the more costly molecular tests [20] . However, the only commercially available, fully automated HCV core antigen assay is the Abbott ARCHITECT HCV cAg assay, which is still complex and laboratory-based. Optimizing tests for core HCV antigen would require the platform to be significantly simplified and made more affordable. The only known pipeline point-of-care test for core antigen is being developed by Daktari and will likely be available in 2017. The batteryoperated, polyvalent, cassette-based test will only require 50 ml of fingerprick blood and deliver a result in 30 min, with a limit of detection equivalent to a viral load of 1000 IU/ml. Although difficult to calculate at this point, the test is likely to cost US$10-20, with volume-based decreases possible (Daktari Diagnostics, personal communication, 11 August 2014). Such a test could be used in a decentralized clinic and be flexible enough to serve a range of diagnostic needs such as CD4 and HIV viral load.
HEPATITIS C VIRUS ANTIGEN TESTING AS A REPLACEMENT FOR HEPATITIS C VIRUS RNA
Importantly, an HCV antigen test that is sufficiently sensitive, specific and low-cost can be used as a onestep screening and diagnostic test rather than the two-step serology and viral load algorithm currently used. As pipeline HCV antigen tests have detection thresholds that correspond to viral loads of 1000-2000 IU/ml, it is important to determine if this level of sensitivity will be sufficient for determining SVR12. There is already evidence from several studies that existing HCV antigen tests have sufficient sensitivity and specificity to replace viral load in HCV diagnosis and proof of cure. A systematic review is currently underway to more fully assess this question. In small convenience samples of 65 patients who experienced virologic failure after becoming undetectable on either PEG-RBV or PEG-RBV and a DAA (bocepravir or sofosbuvir) and had a measure of viral load less than 175 days after completing treatment (SVR24 þ 7 days), only three (4.6%) patients had a viral load (VL) that was detectable but below the limit of detection for the antigen prototypes (<2000 IU/ml). An additional three (4.6%) patients had a VL that was detectable, but below the limit of detection for the antigen prototypes, but the VL was taken before 77 days after the end of therapy (SVR12-7 days). Additional field validation studies and estimates of cost-effectiveness of the one-step versus two-step algorithm are needed before antigen testing becomes the standard of care. Evidence also points to the fact that dried blood spots, a simple method of drying a drop of blood on filter paper for the stable storage of samples at ambient temperature, may be used to more easily transport samples to a central laboratory for virological testing [21, 22] 
CONCLUSION
Taken together, oral therapies in combination with new diagnostic tools will lead to a revolution in laboratory requirements for care of HCV and may lead to cost reductions, allowing a diagnostic and treatment monitoring package to cost as little as US$171-360 [4 && ]. Although the complexity and cost of HCV diagnosis and management should not be used as a reason not to treat patients in clinical need of therapy, it does represent a barrier to the rapid and successful scale up of HCV treatment in L&MICs. Leveraging the strong efficacy and tolerability of DAA-based all-oral therapies will help break down the diagnostic and monitoring barriers. Of course, realizing the health benefits of innovations in HCV care is predicated on ensuring access to those in need globally and this will depend significantly on the price of both drugs and diagnostics. If the financial costs of diagnostics and drugs are too great, HCV may become a disease that is readily curable among those with adequate financial resources and remain a scourge to those without them. In situations where access to treatment is limited, it could be beneficial to include staging tests and only treat those with the most severe disease. However, given that there is a benefit to achieving SVR for patients free of cirrhosis [18] , universal treatment should be recommended where economically feasible. The implementation of low-cost diagnostic, treatment and monitoring packages in L&MICs could be a model for HCV care the world over and move HCV one more step toward global control.
